At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 266 enrolled
Drug / intervention
Nebivolol 5 mg +1 moredrug
Likely dose
Nebivolol 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Open-label, Multicenter, multinAtionaL, inteRventional Clinical Trial to Assess Efficacy and Safety of the exteMporaneous combInation of Nebivolol and Ramipril in hypertenSIve pAtients - ARTEMISIA Study
Menarini International Operations Luxembourg SA·interventional·Posted Oct 27, 2023·Updated Apr 24, 2025
In Brief
A Phase 4 clinical trial evaluating Nebivolol 5 mg and Ramipril 2.5/5/10 mg for Hypertension. Completed, enrolled 266 participants across 1 site.
Detailed Summary
Open-label, inteRventional clinical Trial to assess EffIcacy and safety of the exteMporaneous combInation of Nebivolol and Ramipril in hypertenSIve pAtients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesHungary
Collaborators--
Timeline
Phase 4CompletedFinished
202420252026
Enrollment StartOct 2023
First PostedOct 2023
Primary CompletionFeb 2024
TodayJul 2026
First PostedOct 27, 2023
Enrollment StartOct 2, 2023
Primary CompletionFeb 19, 2024
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 2.7 years ago
Interventions
Nebivolol 5 mgdrug
1 tablet of study medication (5mg) to be administered orally according to instructions of Investigator.
Ramipril 2.5/5/10 mgdrug
1 tablet of study medication (2.5mg or 5mg or 10mg) to be administered orally according to instructions of Investigator.